Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

LY2062430: Multiple-Dose Safety in Subjects With Mild-to-Moderate Alzheimer's Disease and Single-Dose Safety in Healthy Volunteers

To study the safety of LY2062430 in patients with mild-to-moderate Alzheimer's disease and in healthy volunteers.

Inclusion Criteria:

• At least 50 years of age and diagnosed with mild to moderate Alzheimer's disease or healthy volunteers
• fluent in reading and speaking English
• AD patients must have a reliable study partner who will be in frequent contact with the patient and comply with protocol requirements
• AD patients who have received AChEIs or memantine for at least 4 months and on stable therapy for at least 2 months prior to starting study drug

Exclusion Criteria:

• Have a history of serious infectious disease affecting the brain, head trauma, cancer, drug or alcohol abuse in the past 5 years
• Have serious or uncontrolled health problems or laboratory tests
• Multiple or severe drug allergies
• Prior participation in an active immunization study